UK biotech firm confirms Nasdaq float

Nycomed Amersham, a UK biotech company, confirmed plans for a flotation of its drug discovery unit on Nasdaq in the US in March.

The UK firm filed with the US Securities & Exchange Commission in October last year to float 10% of APBiotech on the US market.

WSJ Logo